Charles River Laboratories International, Inc. Common Stock (CRL)
138.79
-2.57 (-1.82%)
NYSE · Last Trade: May 10th, 3:52 PM EDT
Detailed Quote
Previous Close
141.36
Open
141.21
Bid
136.50
Ask
152.70
Day's Range
138.46 - 143.46
52 Week Range
91.86 - 254.15
Volume
920,260
Market Cap
6.99B
PE Ratio (TTM)
-231.32
EPS (TTM)
-0.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,598,974
Chart
About Charles River Laboratories International, Inc. Common Stock (CRL)
Charles River Laboratories International is a global provider of laboratory services that support the pharmaceutical, biotechnology, and medical device industries. The company offers a comprehensive suite of research and development solutions, including essential support for drug discovery, safety assessment, and manufacturing. By providing innovative tools and technologies, as well as expertise in areas such as toxicology and genetic testing, Charles River plays a critical role in advancing biomedical research and helping clients develop and bring new therapies to market efficiently and effectively. Read More
The review aims to enhance shareholder value, with four new independent directors joining the board. Despite a 2.7% drop in Q1 revenue, analysts raised their outlook, boosting retail sentiment.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 17.3% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat analysts' organic revenue and EPS estimates, and featured a raise to full-year EPS guidance. Zooming out, we think this was a solid print.
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 2.7% year on year to $984.2 million. Its non-GAAP profit of $2.34 per share was 12.8% above analysts’ consensus estimates.
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company’s business focused on enhancing long-term value for shareholders.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the initial cohort of its Charles River Incubator Program (CIP). Launched in December 2024, the program offers early-stage biotechnology pioneers access to extensive scientific and commercial expertise and a wide ecosystem of discovery, development, and manufacturing capabilities to expedite the development of technologies and life-changing therapies for patients in need.
Charles River Laboratories International, Inc. (NYSE: CRL), ahead of the American Association for Cancer Research® (AACR) Annual Meeting in Chicago, IL, has announced updates to its comprehensive portfolio of products and services supporting the discovery and development of novel oncology drugs. Based solely on projected population growth, the number of cancer cases is predicted to increase to 35 million by 2050, and approximately 1 in 5 individuals will develop cancer in their lifetime.
